Spinal Muscular Atrophy (SMA) Clinical Trial
Official title:
A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Risdiplam works by helping the body produce more survival motor neuron (SMN) protein throughout the body. This means fewer motor neurons - nerve cells that pass impulses from nerves to muscles to cause movement - are lost, which may improve how well muscles work in people with SMA. RO7204239 is an investigational anti-myostatin antibody that is designed to target myostatin. Myostatin plays an important role in the regulation of skeletal muscle size by controlling growth. Inhibiting myostatin may help muscles grow in size and strength. RO7204239 in combination with risdiplam, which is designed to increase the amount of SMN protein throughout the body, has the potential to further improve motor function and clinical outcomes for people living with SMA. This trial will study the safety and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy (SMA). The trial has two parts; Part 1 is the dose-finding part in SMA patients that are either ambulant (aged 2-10 years) or non-ambulant (aged 5-10 years) within separate cohorts, and Part 2 is the pivotal part in SMA patients aged 2-25 years that are ambulant.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04174157 -
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
|
||
| Recruiting |
NCT05354414 -
Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy
|
N/A | |
| Terminated |
NCT02876094 -
Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
| Recruiting |
NCT05747261 -
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
|
Phase 1/Phase 2 | |
| Completed |
NCT01736553 -
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
|
||
| Recruiting |
NCT05335876 -
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
|
Phase 3 | |
| Withdrawn |
NCT01663584 -
Multi-disease Carrier Screening Test Validation
|
N/A |